非奈利酮的正确购买途径

Introduction: Fenelidone is a drug used to treat chronic kidney disease related to type 2 diabetes. In recent years, it has received widespread attention due to its significant efficacy. With the introduction of generic drugs, patients have more choices when choosing their medications. This article will discuss in detail the correct way to purchase generic Fenelidone, its efficacy, and its use in special populations to help patients better understand and use this drug.

The correct purchasing channel for nonelidone generic drugs

Choosing the correct purchasing channel is the key to ensuring the quality of generic drugs. The following will analyze three channels: hospital pharmacies, online pharmacies and physical pharmacies.

Hospital pharmacy

Purchasing generic nonelidone drugs through regular hospital pharmacies is one of the most reliable ways. Hospital pharmacies can usually provide regular drugs and professional medication guidance to ensure the quality and safety of drugs.

Online pharmacies

With the development of the Internet, more and more online pharmacies have begun to sell generic versions of fenelidone, and patients can purchase them through regular pharmaceutical e-commerce platforms. This method is not only convenient and fast, but also provides detailed drug information and user reviews to help patients make more informed choices.

Physical pharmacies

Patients can also go to local regular large pharmacies to purchase medicines. A medical prescription is required before purchasing medicines.

Understanding the correct way to purchase generic nonelidone drugs will help patients choose the appropriate way to purchase drugs according to their own needs.

The Efficacy of Fenelidone

Finelidone has significant efficacy in the treatment of chronic kidney disease associated with type 2 diabetes.

Urine protein-lowering effect

Fenelinone can significantly reduce the urinary albumin/creatinine ratio (UACR), thereby reducing the excretion of urinary protein. Clinical studies have shown that UACR in patients treated with fenelidone was relatively reduced at 4 months and remained stable during the trial.

Delay the decline of renal function

Fenelinone can delay the decline of glomerular filtration rate (eGFR), thereby delaying the deterioration of renal function. In the FIDELIO-DKD study, fenelidone significantly reduced the incidence of sustained eGFR decline of ≥40% from baseline and reduced the risk of renal failure.

Cardioprotective effects

Fenelinone also has cardiovascular protective effects, reducing the risk of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure. In the FIGARO-DKD study, fenelinone significantly reduced the incidence of these cardiovascular events.

Understanding the efficacy of fenelinone can help patients better understand the therapeutic effect of the drug and enhance their confidence in taking the drug.

Fenelidone use in special populations

The use of fenelidone in certain special populations requires special attention. The following will be discussed from three aspects: the elderly, patients with hepatic insufficiency, and patients with renal insufficiency.

Elderly

In the FIDELIO-DKD and FIGARO-DKD studies, 55% of patients were ≥65 years old, and 14% were ≥75 years old. No overall differences in safety or efficacy were observed between these patients and younger patients. Therefore, no dose adjustment is required in elderly patients.

Patients with hepatic impairment

Patients with severe hepatic impairment should not initiate fenelidone therapy. In patients with moderate hepatic impairment, additional monitoring may be required with dose adjustments based on the patient's condition. Fenelidone exposure was not clinically significantly affected in patients with mild hepatic impairment.

Patients with renal insufficiency

The risk of hyperkalemia increases with decreasing renal function. Finelidone therapy should not be initiated in patients with eGFR <25 mL/min/1.73 m². Patients who progress to end-stage renal disease (eGFR <15 mL/min/1.73 m²) should discontinue fenelidone therapy.

Understanding the precautions for the use of fenelidone in special groups will help patients conduct a full assessment before use and avoid unnecessary health risks.